Why the study?
Does ethmozin reduce ventricular premature complexes in patients with chronic, persistent, frequent and symptomatic VPCs?
Does ethmozin reduce ventricular premature complexes in patients with chronic, persistent, frequent and symptomatic VPCs?
Ethmozin at 600 mg/day appears to be a well-tolerated and effective agent for suppressing ventricular premature complexes.
Answers are grounded in this paper and cite their sources.
May support higher-dose ethmozin for symptomatic VPCs; leaves open efficacy and safety without randomized trials.
Ethmozin, a phenothiazine derivative, is an antiarrhythmic drug synthesized in the USSR. Preliminary data suggest that it is effective against a diversity of ectopic arrhythmias. The present study, carried out in the USSR, was designed to assess efficacy and patient tolerance of this new drug. Thirty-seven patients with chronic, persistent, frequent and symptomatic ventricular premature complexes (VPCs) were studied. VPCs were exposed by means of 24-hour ambulatory monitoring and exercise stress testing. Two drug schedules were used. Group 1, consisting of 11 patients, received 225 mg/day of ethmozin, while group 2, consisting of 26 patients, received 600 mg/day. Acute drug testing with a single large dose of ethmozin was followed by multiple dosing for a minimum of 4 days. Placebo was given in a single-blind fashion only to responders. Only two patients in group 1 had a significant reduction in VPCs as evaluated by both monitoring and exercise testing. Fourteen patients in group 2 (54%) showed striking suppression of VPCs. Mild and transiet effects were encountered in only four of the 37 patients. We conclude that ethmozin appears to be a well-tolerated, relatively effective agent for controlling VPCs.
No takes yet. Share an insight, caveat, or question.
Podrid et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: